Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo de estudio
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Bioorg Med Chem Lett ; 23(5): 1498-501, 2013 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-23333208

RESUMEN

A series of tetrahydroisoquinolines were designed, synthesized and evaluated as the first non-natural product type of compounds with dual D(1) receptor (D(1)R) agonism and D(2) receptor (D(2)R) antagonism properties for treatment of schizophrenia. The initial SAR of the series was explored. The lead in the series, 3g, exhibited high affinity and good potency. Compound 3g displayed 95% of D(1)R occupancy (10 mg/kg, sc) and 75% of D(2)R occupancy (10 mg/kg, sc) in the striatum of male CD-1 mice. The series exhibited unique pharmacology and merit as tool compounds for target validation and future optimizations.


Asunto(s)
Antagonistas de los Receptores de Dopamina D2 , Receptores de Dopamina D1/agonistas , Esquizofrenia/tratamiento farmacológico , Tetrahidroisoquinolinas/química , Tetrahidroisoquinolinas/farmacología , Animales , Diseño de Fármacos , Masculino , Ratones , Receptores de Dopamina D1/metabolismo , Receptores de Dopamina D2/metabolismo , Esquizofrenia/patología , Relación Estructura-Actividad , Tetrahidroisoquinolinas/síntesis química
2.
Eur J Pharmacol ; 450(1): 37-41, 2002 Aug 16.
Artículo en Inglés | MEDLINE | ID: mdl-12176106

RESUMEN

Many antipsychotic drugs produce QT interval prolongation on the electrocardiogram (ECG). Blockade of the human cardiac K(+) channel known as human ether-a-go-go-related gene (HERG) often underlies such clinical findings. In fact, HERG channel inhibition is now commonly used as a screen to predict the ability of a drug to prolong QT interval. However, the exact relationship between HERG channel blockade, target receptor binding affinity and clinical QT prolongation is not known. Using patch-clamp electrophysiology, we examined a series of seven antipsychotic drugs for their ability to block HERG, and determined their IC(50) values. We then compared these results to their binding affinities (K(i) values) for the dopamine D(2) receptor, the 5-HT(2A) receptor and, where available, to clinical QT prolongation data. We found that sertindole, pimozide and thioridazine displayed little (<10-fold) or no selectivity for dopamine D(2) or 5-HT(2A) receptors relative to their HERG channel affinities. This lack of selectivity likely underlies the significant QT interval prolongation observed with administration of these drugs. Of the other drugs tested (ziprasidone, quetiapine, risperidone and olanzapine), olanzapine displayed the greatest selectivity for dopamine D(2) and 5-HT(2A) receptor binding (100-1000-fold) compared to its HERG channel IC(50). We also compared these HERG channel IC(50) values to QT interval prolongation and plasma drug levels obtained in a recent clinical study. We found that the ratio of total plasma drug concentration to HERG IC(50) value was indicative of the degree of QT prolongation observed. Target receptor affinity and expected clinical plasma levels are important parameters to consider for the interpretation of HERG channel data.


Asunto(s)
Antipsicóticos/farmacología , Proteínas de Transporte de Catión , Proteínas de Unión al ADN , Bloqueadores de los Canales de Potasio/farmacología , Canales de Potasio con Entrada de Voltaje , Canales de Potasio/efectos de los fármacos , Canales de Potasio/metabolismo , Transactivadores , Animales , Antipsicóticos/efectos adversos , Antipsicóticos/sangre , Línea Celular , Ensayos Clínicos como Asunto , Cricetinae , Canal de Potasio ERG1 , Canales de Potasio Éter-A-Go-Go , Humanos , Síndrome de QT Prolongado/inducido químicamente , Técnicas de Placa-Clamp , Bloqueadores de los Canales de Potasio/efectos adversos , Bloqueadores de los Canales de Potasio/sangre , Canales de Potasio/fisiología , Ensayo de Unión Radioligante , Receptor de Serotonina 5-HT2A , Receptores de Dopamina D2/efectos de los fármacos , Receptores de Dopamina D2/fisiología , Receptores de Serotonina/efectos de los fármacos , Receptores de Serotonina/fisiología , Regulador Transcripcional ERG
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA